Search - tctmd.com

Displaying 61 - 80 of 110

Sort: Relevancy | Date

Presentation TVT 2017

Cardiogenic Shock Secondary to Acute Left Main Occlusion Post Transcatheter Aortic Valve Replacement

Presenter: David W.M. Muller, Lars Sondergaard, Jaspreet Singh, MD

June 16, 2017

Presentation TVT 2017

Three-dimensional Modeling of Coronary Occlusion During Transcatheter Aortic Valve Replacement

Presenter: David W.M. Muller, Lars Sondergaard, Scott Lilly, MD

June 16, 2017

Presentation TVT 2017

Featured Lecture: The Spectrum of Bioprosthetic Valve Leaflet Thrombosis: From "Subclinical" Leaflet Thickening to Hemodynamic Changes and Clinical Events

Presenter: David W.M. Muller, Lars Sondergaard

June 16, 2017

Presentation EuroPCR 2017

Longevity of Transcatheter and Surgical Bioprosthetic Aortic Valves

Presenter: Lars Sondergaard

May 19, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

Presentation TCT 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Presentation TCT 2016

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

Late (>5 years) Clinical and Echo Outcomes After TAVR II: The Vancouver Experience

Presenter: Raj Makkar, Lars Sondergaard, John G. Webb

October 31, 2016

Presentation TCT 2016

Late (>5 years) Clinical and Echo Outcomes After TAVR I: The Rouen Experience

Presenter: Raj Makkar, Lars Sondergaard, Helene Eltchaninoff

October 31, 2016

Presentation TCT 2016

Controversy 3. Surgical Perspectives on Late Bioprosthetic Valve Durability

Presenter: Raj Makkar, Lars Sondergaard, A. Pieter Kappetein

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Presenter: Raj Makkar, Lars Sondergaard, Haim Danenberg

October 31, 2016

Presentation TCT 2016

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Presenter: Raj Makkar, Lars Sondergaard, Axel Linke

October 31, 2016

Presentation TCT 2016

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia

October 31, 2016

Advertisement

Cardiogenic Shock Secondary to Acute Left Main Occlusion Post Transcatheter Aortic Valve Replacement

Three-dimensional Modeling of Coronary Occlusion During Transcatheter Aortic Valve Replacement

Featured Lecture: The Spectrum of Bioprosthetic Valve Leaflet Thrombosis: From "Subclinical" Leaflet Thickening to Hemodynamic Changes and Clinical Events

Longevity of Transcatheter and Surgical Bioprosthetic Aortic Valves

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

Late (>5 years) Clinical and Echo Outcomes After TAVR II: The Vancouver Experience

Late (>5 years) Clinical and Echo Outcomes After TAVR I: The Rouen Experience

Controversy 3. Surgical Perspectives on Late Bioprosthetic Valve Durability

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content